A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Venetoclax
DRUG: Rituximab

Sponsor

Loxo Oncology, Inc.

Collaborators

[object Object]